JP2002541199A5 - - Google Patents

Download PDF

Info

Publication number
JP2002541199A5
JP2002541199A5 JP2000610470A JP2000610470A JP2002541199A5 JP 2002541199 A5 JP2002541199 A5 JP 2002541199A5 JP 2000610470 A JP2000610470 A JP 2000610470A JP 2000610470 A JP2000610470 A JP 2000610470A JP 2002541199 A5 JP2002541199 A5 JP 2002541199A5
Authority
JP
Japan
Prior art keywords
formula
compound
alkyl
hydrogen
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000610470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002541199A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/008338 external-priority patent/WO2000061137A1/en
Publication of JP2002541199A publication Critical patent/JP2002541199A/ja
Publication of JP2002541199A5 publication Critical patent/JP2002541199A5/ja
Pending legal-status Critical Current

Links

JP2000610470A 1999-04-08 2000-03-30 脂質を下げることに有用な抗痙攣薬誘導体 Pending JP2002541199A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12840199P 1999-04-08 1999-04-08
US60/128,401 1999-04-08
PCT/US2000/008338 WO2000061137A1 (en) 1999-04-08 2000-03-30 Anticonvulsant derivatives useful in lowering lipids
US09/538,185 2000-03-30
US09/538,185 US6191163B1 (en) 1999-04-08 2000-03-30 Anticonvulsant derivatives useful in lowering lipids

Publications (2)

Publication Number Publication Date
JP2002541199A JP2002541199A (ja) 2002-12-03
JP2002541199A5 true JP2002541199A5 (enExample) 2007-02-15

Family

ID=26826550

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000610470A Pending JP2002541199A (ja) 1999-04-08 2000-03-30 脂質を下げることに有用な抗痙攣薬誘導体

Country Status (7)

Country Link
US (1) US6191163B1 (enExample)
JP (1) JP2002541199A (enExample)
AU (1) AU774732B2 (enExample)
CA (1) CA2369093C (enExample)
MX (1) MXPA01010218A (enExample)
NZ (1) NZ514810A (enExample)
WO (1) WO2000061137A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL365680A1 (en) * 2000-07-07 2005-01-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for preventing the development of type ii diabetes mellitus and syndrome x
ES2269297T3 (es) 2000-10-30 2007-04-01 Ortho-Mcneil Pharmaceutical, Inc. Combinacion terapeutica que contiene agentes antidiabeticos y anticonvulsivos.
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
CA2578407A1 (en) * 2004-08-24 2006-03-02 Janssen Pharmaceutica N.V. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
MX2007014613A (es) * 2005-05-20 2008-04-02 Johnson & Johnson Procedimiento para la preparacion de derivados de sulfamida.
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191453A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191459A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
EP2026790A2 (en) * 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy and related disorders
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
WO2010008776A2 (en) 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Disposable patch and reusable sensor assembly for use in medical device localization and mapping systems
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
SK284305B6 (sk) * 1996-06-28 2005-01-03 Ortho-Mcneil Pharmaceutical, Inc. Liečivo na liečbu obezity
JP2001240593A (ja) * 1999-10-12 2001-09-04 Japan Tobacco Inc 高トリグリセリド血症治療薬及び抗肥満薬

Similar Documents

Publication Publication Date Title
JP2002541199A5 (enExample)
JP2004505004A5 (enExample)
JP2003521471A5 (enExample)
JP2003501474A5 (enExample)
CA2373653C (en) New use of compounds as antibacterial agents
RU2003100076A (ru) Противосудорожные производные, используемые для профилактики развития сахарного диабета и синдрома х
NO20100034L (no) Fenofibrat farmasoytisk blanding som har hoy biotilgjengelighet og fremgangsmate for fremstilling av den
CA2139653A1 (en) Optically pure salts of pyridinylmethyl sulfinyl-ih- benzimidazole compounds
AR017979A1 (es) Formulaciones farmaceuticas de epotilonas, metodo para su preparacion y el uso de los mismos para la manufactura de un medicamento
AU658619B2 (en) Benzopyranones, methods of manufacture and use thereof
CA2294337A1 (en) Preparation of pharmaceutical compositions
BR0015567A (pt) Compostos de ácido fenoxicarboxìlico e composições para liberar agentes ativos
JPS6422822A (en) Solid drug preparation and manufacture
JP2003500442A5 (enExample)
JP2002544173A5 (enExample)
CA2329217A1 (en) Stable extended release oral dosage composition comprising desloratadine and pseudoephedrine
MY118156A (en) Oral compositions of levosimendan.
JP2003514872A5 (enExample)
LV11103A (lv) Perorali lietojama zalu forma centralas nervu sistemas dofamina deficita stavoklu arstesanai
CA2345445A1 (en) A composition for the prevention and/or treatment of atherosclerosis
CA2369093A1 (en) Anticonvulsant derivatives useful in lowering lipids
DE69608896D1 (de) Zubereitungen enthaltend leflunomide
KR970706792A (ko) 수불용성 캄프토테신의 지질 복합체의 동결 건조물(Lyophilizate of lipid complex of water insoluble camptothecins)
JP2002536328A5 (enExample)
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents